The Emergence of NK Cell-Based Treatment in Cancer Immunotherapy

By Olivier Lucar
August 20, 2019

The 2018 Nobel Prize in Physiology or Medicine was awarded to James Alison and Tasuku Honjo for their groundbreaking work on cancer therapy targeting the inhibition of immune checkpoints (IC), proteins that negatively regulate the immune response. Their work was groundbreaking because it opened a new powerful tool for the cure of cancer—immunotherapy (Fritz J. et Lenardo M., 2019).

The Cancer Revolution

At the beginning of cancer research, the immune system was not considered an important actor in cancer pathogenesis. But, in fact, the tumor microenvironment is Continue reading “The Emergence of NK Cell-Based Treatment in Cancer Immunotherapy”

How CAR-T Cell Therapy is Impacting Solid Tumor Cancer Research

By David Haas
Wednesday June 5, 2019

Treatment options available to cancer patients have both improved and grown over the past decade. The development of personalized medicine has enabled patients to seek a new route, tailoring their treatments specifically to their situations. One outcome of this unique treatment approach is the development of CAR-T (chimeric antigen receptor T) cell therapy (see: Taking Personalized Medicine to a New Level: CAR-T Cell Therapy). Continue reading “How CAR-T Cell Therapy is Impacting Solid Tumor Cancer Research”

Taking Personalized Medicine to a New Level: CAR-T Cell Therapy

By Martina McGrath, MD
September 13, 2017

Each individual is estimated to have around 4 x 1011 T cells, comprising many millions of T cell clones,1 each randomly produced in the thymus with a unique T cell receptor (TCR) specific for a given antigen. This massive diversity in T cell repertoire gives our immune systems the capacity to protect against the incredible array of bacteria, viruses and fungi that assail us on a constant basis. Continue reading “Taking Personalized Medicine to a New Level: CAR-T Cell Therapy”